Joshua M. Eizen
Known title: Chief Legal OfficerCIK: 0001949621
Associated companies
Transaction History
| ANTX | ▼ Sell | Open Market | 5,945 | $25K | 7/8/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 50,000 | $0 | 2/20/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 6,931 | $7K | 1/6/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 17,923 | $18K | 1/5/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 2,819 | $3K | 11/4/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 58,500 | $0 | 2/26/2025 | View on chart |
| ANTX | ▼ Sell | Open Market | 9,663 | $13K | 1/3/2025 | View on chart |
| ANTX | ▲ Buy | Grant | 31,500 | $0 | 11/4/2024 | View on chart |
| ANTX | ▲ Buy | Grant | 60,000 | $0 | 7/10/2024 | View on chart |
| ANTX | ▲ Buy | Grant | 30,000 | $0 | 3/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AN2 Therapeutics: Failed Drug Potential Value Driver
Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.
AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.